Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1

Documenti analoghi

• Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen
  di: von Hentig, Nils, et al.
  Pubblicazione: (2008)
• Cytochrome P450 3A Inhibition by Atazanavir and Ritonavir, but Not Demography or Drug Formulation, Influences Saquinavir Population Pharmacokinetics in Human Immunodeficiency Virus Type 1-Infected Adults
  di: von Hentig, Nils, et al.
  Pubblicazione: (2009)
• Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen
  di: von Hentig, Nils, et al.
  Pubblicazione: (2007)
• Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214
  di: Stürmer, Martin, et al.
  Pubblicazione: (2003)
• Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy
  di: von Hentig, Nils
  Pubblicazione: (2015)